Coya Therapeutics (Coya Therapeutics) Total Current Assets : $37.33 Mil (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Coya Therapeutics Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Coya Therapeutics's total current assets for the quarter that ended in Mar. 2024 was $37.33 Mil.

Coya Therapeutics Total Current Assets Historical Data

The historical data trend for Coya Therapeutics's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Coya Therapeutics Total Current Assets Chart

Coya Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Total Current Assets

8.75

4.58

7.19

41.20

Coya Therapeutics Quarterly Data
	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Current Assets	Get a 7-Day Free Trial						17.33	14.39	11.82	41.20	37.33

Coya Therapeutics Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Coya Therapeutics's Total Current Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	32.627	+	7.5	+	0	+	1.069
	=	41.20

Coya Therapeutics's Total Current Assets for the quarter that ended in Mar. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	35.989	+	0	+	0	+	1.345
	=	37.33

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Coya Therapeutics (NAS:COYA) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Coya Therapeutics's Liquidation Value for the quarter that ended in Mar. 2024 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	35.989	-	5	+	0.75 * 0	+	0.5 * 0
=	30.99

Coya Therapeutics Total Current Assets Related Terms

Thank you for viewing the detailed overview of Coya Therapeutics's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Coya Therapeutics (Coya Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Coya Therapeutics Inc (NAS:COYA) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

5850 San Felipe Street, Suite 500, Houston, TX, USA, 77057

Website

https://www.coyatherapeutics.com

Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.

Executives

Dieter Weinand	director	C/O REPLIMUNE GROUP, INC., 18 COMMERCE WAY, WOBURN MA 01801
Fred Grossman	officer: Chief Medical Officer	C/O COYA THERAPEUTICS, INC., 5850 SAN FELIPE ST., SUITE 500, HOUSTON TX 77057
Goldstein Dov A Md	director
Adrian Hepner	officer: Chief Medical Officer	C/O COYA THERAPEUTICS, INC., 5850 SAN FELIPE ST., SUITE 500, HOUSTON TX 77057
David S Snyder	officer: Chief Financial Officer	ONE SCIENCE COURT, MADISON WI 53711
Hideki Garren	director	C/O PROTHENA BIOSCIENCES INC, 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Anabella Villalobos	director	C/O COYA THERAPEUTICS, INC., 5850 SAN FELIPE ST., SUITE 500, HOUSTON TX 77057
Howard Berman	director, 10 percent owner, officer: Chief Executive Officer	C/O COYA THERAPEUTICS, INC., 5850 SAN FELIPE ST., SUITE 500, HOUSTON TX 77057
Ann Lee	director	C/O COYA THERAPEUTICS, INC., 5850 SAN FELIPE ST., SUITE 500, HOUSTON TX 77057
Bertex Llc	10 percent owner	5850 SAN FELIPE ST., SUITE 500, HOUSTON TX 77057